CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.040
0.00 (0.00%)
At close: Nov 13, 2026, 4:00 PM EST
2.040
0.00 (0.00%)
Pre-market: Nov 16, 2026, 4:03 AM EST
CytomX Therapeutics Stock Forecast
CTMX's stock price has decreased by -51.77% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 8 analysts polled by S&P Global, CytomX Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $12.38. The average 1-year stock price forecast is 506.86% higher than the current stock price, while the lowest is $5.00 (+145.10%) and the highest is $16 (+684.31%).
Price Target: $12.38 (+506.86%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CytomX Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Maintains $11 → $12 | Buy | Maintains | $11 → $12 | +488.24% | Nov 12, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $12 | Buy | Maintains | $12 | +488.24% | Nov 6, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $12 | Buy | Reiterates | $12 | +488.24% | Nov 6, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $14 | Buy | Maintains | $14 | +586.27% | Nov 6, 2026 |
| Wedbush | Wedbush | Buy Maintains $11 → $12 | Buy | Maintains | $11 → $12 | +488.24% | Nov 6, 2026 |
Financial Forecast
Revenue This Year
21.96M
from 76.20M
Decreased by -71.19%
Revenue Next Year
29.98M
from 21.96M
Increased by 36.55%
EPS This Year
-0.39
from -0.15
EPS Next Year
-0.50
from -0.39
EPS and Forward PE are based on non-GAAP adjusted numbers.